EDINBURGH, Scotland, Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally approved the recently announced 25% stock dividend.

Today, TC BioPharm declared that last week's proposed special stock dividend was formally approved at today's General Meeting of the Company. The special dividend of 0.25 American Depositary Shares ("ADSs") for every 1 ADS held by shareholders on the record date of January 2, 2025 are expected to be delivered to shareholders on or about January 6th.

TC BioPharm CEO, Bryan Kobel stated: "Rewarding additional shares to shareholders in the form of this special dividend is an important and effective component of our capital management strategy. It also reflects management's strong confidence in the Company's financial future. I anticipate 2025 to be a period of growth and development for our Company as we remain focused on delivering improved value for our shareholders."

Per Nasdaq requirements, trading in the Company's ADSs will temporarily stop at 5:00 pm on January 2, 2025, and recommence on or around January 8, 2025, to allow the Depositary to process the stock dividend. Nasdaq will adjust the opening price on January 8 to reflect the dilution impact of the stock dividend.

This press release is for informational purposes only. It shall not constitute an offer to sell or exchange nor the solicitation of an offer to buy shares of the Company's common stock or any other securities. For additional information regarding TC BioPharm's General Meeting see our website and filings to be made on form 6K.

About TC BioPharm (Holdings) PLC

TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T-cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.

TC BioPharm is the leader in developing gamma-delta T cell therapies and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in the treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.

Forward-Looking Statements for TC BioPharm

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.

SOURCE TC BioPharm